Antioxidants for chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 10, 2012, Pages

  Jun, Min ^a   Venkataraman, Vinod ^b   Razavian, Mona ^a   Cooper, Bruce ^c   Zoungas, Sophia ^d   Ninomiya, Toshiharu ^a   Webster, Angela C ^e,f,g   Perkovic, Vlado ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; BARDOXOLONE METHYL; CREATININE; SUPEROXIDE DISMUTASE; UBIQUINONE;

ADVERSE EVENT; ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; END STAGE RENAL DISEASE; GENDER; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MALIGNANT NEOPLASM; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; STAGING; SYSTEMATIC REVIEW; THERAPY EFFECT; BLOOD; CHRONIC DISEASE; DISEASE COURSE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; META ANALYSIS; MORTALITY; RENAL REPLACEMENT THERAPY;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CREATININE; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS;

EID: 84871865822     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008176.pub2     Document Type: Review

References (74)

1. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, et al.Bardoxolone methyl and kidney function in CKD with type 2 diabetes. New England Journal of Medicine 2011;365(4):327-36. [MEDLINE: 21699484].
2. Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J, et al.Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney International 2004;65(4):1375-80. [MEDLINE: 15086477].
3. McQueen MJ, Lonn E, Gerstein HC, Bosch J, Yusuf S. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scandinavian Journal of Clinical & Laboratory Investigation Supplement 2005;240:143-56. [MEDLINE: 16112972].
4. Land W, Schneeberger H, Schleibner S, Illner WD, Abendroth D, Rutili G, et al.The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994;57(2):211-7. [MEDLINE: 8310510].
5. Pollak R, Andrisevic JH, Maddux MS, Gruber SA, Paller MS. A randomized double-blind trial of the use of human recombinant superoxide dismutase in renal transplantation. Transplantation 1993;55(1):57-60. [MEDLINE: 8420065].
6. Rabl H, Khoschsorur G, Colombo T, Petritsch P, Rauchenwald M, Költringer P, et al.A multivitamin infusion prevents lipid peroxidation and improves transplantation performance. Kidney International 1993;43(4):912-7. [MEDLINE: 8479129].
7. Shoskes D, Lapierre C, Cruz-Correa M, Muruve N, Rosario R, Fromkin B, et al.Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation 2005;80(11):1556-9. [MEDLINE: 16371925].
8. Singh RB, Khanna HK, Niaz MA. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in chronic renal failure: Discovery of a new role. Journal of Nutritional & Environmental Medicine 2000;10(4):281-8. [EMBASE: 2001029318].
9. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al.Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356(9237):1213-8. [MEDLINE: 11072938].
10. Boaz M, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, et al.Secondary prevention using antioxidants of cardiovascular disease in endstage renal disease:SPACE [abstract]. Nephrology Dialysis Transplantation 2000;15(9):A11.
11. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003;107(7):992-5. [MEDLINE: 12600912].
12. Wijnen MH, Vader HL, van den Wall Bake AW, Roumen RM. Can renal dysfunction after infra-renal aortic aneurysm repair be modified by multi-antioxidant supplementation?. Journal of Cardiovascular Surgery 2002;43(4):483-8. [MEDLINE: 12124559].
13. Abendroth D, Schneeberger H, Schleibner S, Illner WD, Land W. Status of treatment with free radical scavengers following kidney and pancreas transplantation. Zentralblatt für Chirurgie 1992;117(9):502-8. [MEDLINE: 1441789].
14. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney International 2004;65(6):2279-89. [MEDLINE: 15149341].
15. Nanayakkara PW, van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW, et al.Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Archives of Internal Medicine 2007;167(12):1262-70. [MEDLINE: 17592099].
16. Nanayakkara PWB, van Guldener C, van Ittersum F, Stehouwer CDA, ter Wee PM. Effect of an oxidative-stress-reducing strategy on carotid intima-media thickness, endothelial function and renal function in patients with mild-to-moderate chronic kidney disease [abstract]. Journal of the American Society of Nephrology 2006;17(Abstracts):367A.
17. Blackhall ML, Fassett RG, Sharman JE, Geraghty DP, Coombes JS. Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients. Nephrology Dialysis Transplantation 2005;20(9):1970-5. [MEDLINE: 15998657].
18. Mune M, Yukawa S, Kishino M, Otani H, Kimura K, Nishikawa O, et al.Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney International - Supplement 1999;71:S126-9. [MEDLINE: 10412755].
19. Noel C, Copin MC, Hazzan M, Labalette M, Susen S, Lelievre G, et al.Immunomodulatory effect of pentoxifylline during human allograft rejection: involvement of tumor necrosis factor-alpha and adhesion molecules. Transplantation 2000;69(6):1102-7. [MEDLINE: 10762214].
20. Panzetta O, Cominacini L, Garbin U, Fratta Pasini A, Gammaro L, Bianco F, et al.Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration. Clinical Nephrology 1995;44(5):303-9. [MEDLINE: 8605710].
21. Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. American Journal of Kidney Diseases 2009;53(4):606-16. [MEDLINE: 19216016].
22. Schneeberger H, Illner WD, Abendroth D, Bulkley G, Rutili F, Williams M, et al.First clinical experiences with superoxide dismutase in kidney transplantation--results of a double-blind randomized study. Transplantation Proceedings 1989;21(1 Pt 2):1245-6. [MEDLINE: 2652409].
23. Schramm L, La M, Heidbreder E, Hecker M, Beckman J S, Lopau K, et al.L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney International 2002;61(4):1423-32. [MEDLINE: 11918749].
24. Wlodarczyk Z, Oko A, Glyda M, Karczewski M, Idasiak-Piechocka I, Czekalski S. Effects of pentoxifylline treatment on delayed graft function in cadaveric kidney recipients. Transplantation Proceedings 2000;32(6):1382-3. [MEDLINE: 10995988].
25. Yukawa S, Hibino A, Maeda T, Mimura K, Yukawa A, Maeda A, et al.Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in haemodialysis patients. Nephrology Dialysis Transplantation 1995;10 Suppl 3:1-3. [MEDLINE: 7494606].
26. BEACON Study. Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON). http://www.clinicaltrials.gov/show/NCT01351675 (accessed August 2012).
27. Excell L, Russ GR, Wride P (editors). Australia and New Zealand Organ Donation Registry. ANZOD 2004 Annual Report. http://www.anzdata.org.au/anzod/anzodreport/2004/2004Contents.pdf (accessed August 2012).
28. Bachem MG, Wendelin D, Schneiderhan W, Haug C, Zorn U, Gross HJ, et al.Depending on their concentration oxidized low density lipoproteins stimulate extracellular matrix synthesis or induce apoptosis in human coronary artery smooth muscle cells. Clinical Chemistry & Laboratory Medicine 1999;37(3):319-26. [MEDLINE: 10353478].
29. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD007176].
30. Brunet J, Boily MJ, Cordeau S, Des Rosiers C. Effects of N-acetylcysteine in the rat heart reperfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow. Free Radical Biology & Medicine 1995;19(5):627-38. [MEDLINE: 8529922].
31. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al.A randomized, controlled trial of early versus late initiation of dialysis. New England Journal of Medicine 2010;363(7):609-19. [MEDLINE: 20581422].
32. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. Journal of the American Society of Nephrology 2006;17(8):2100-5. [MEDLINE: 16825327].
33. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. Journal of the American College of Cardiology 1996;28(2):506-14. [MEDLINE: 8800132].
34. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al.Effect of dialysis dose and membrane flux in maintenance hemodialysis. New England Journal of Medicine 2002;347(25):2010-9. [MEDLINE: 12490682].
35. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proceedings of the National Academy of Sciences of United States of America 1989;86(16):6377-81. [MEDLINE: 2762330].
36. Galle J, Heermeier K, Wanner C. Atherogenic lipoproteins, oxidative stress and cell death. Kidney International - Supplement 1999;71:S62-5. [MEDLINE: 10412740].
37. Anonymous. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354(9177):447-55. [MEDLINE: 10465168].
38. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension and cardiovascular disease: which role for oxidative stress?. Metabolism: Clinical & Experimental 1995;44(3):363-8. [MEDLINE: 7885282].
39. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 1994;344(8924):721-4. [MEDLINE: 7915779].
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):23-33. [MEDLINE: 12114037].
41. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120].
42. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
43. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney International 2000;58(6):2571-8. [MEDLINE: 11115093].
44. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney International 2002;62(5):1524-38. [MEDLINE: 12371953].
45. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 2002;287(21):2801-4. [MEDLINE: 12038917].
46. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000;150(1):217-24. [MEDLINE: 10781654].
47. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circulation Research 1984;54(3):277-85. [MEDLINE: 6697450].
48. Kaul N, Siveski-Iliskovic N, Thomas TP, Hill M, Khaper N, Singal PK. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995;11(5 Suppl):551-4. [MEDLINE: 8748220].
49. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 4. Definition and classification of stages of chronic kidney disease. American Journal of Kidney Diseases 2002;39(2 Suppl 1):S46-75. [MEDLINE: 11904577].
50. Kukreja RC, Hess ML. The oxygen free radical system: from equations through membrane-protein interactions to cardiovascular injury and protection. Cardiovascular Research 1992;26(7):641-55. [MEDLINE: 1423428].
51. Kukreja RC Hess ML. Free radicals, cardiovascular dysfunction and protection strategies. Austin: RG Landes Co, 1994. [ISBN: 1570590125].
52. Landray MJ, Thambyrajah J, McGlynn FJ, Jones HJ, Baigent C, Kendall MJ, et al.Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. American Journal of Kidney Diseases 2001;38(3):537-46. [MEDLINE: 11532686].
53. Lee V, Randhawa AK, Singal PK. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. American Journal of Physiology 1991;261(4 Pt 2):H989-95. [MEDLINE: 1928418].
54. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. American Journal of Kidney Diseases 1990;15(5):458-82. [MEDLINE: 2333868].
55. Meydani M, Martin A, Ribaya-Mercado JD, Gong J, Blumberg JB, Russell RM. Beta-carotene supplementation increases antioxidant capacity of plasma in older women. Journal of Nutrition 1994;124(12):2397-403. [MEDLINE: 16856320].
56. Peng M, Huang L, Xie ZJ, Huang WH, Askari A. Oxidant-induced activations of nuclear factor-kappa B and activator protein-1 in cardiac myocytes. Cellular & Molecular Biology Research 1995;41(3):189-97. [MEDLINE: 8589759].
57. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369(9559):381-8. [MEDLINE: 17276778].
58. Prasad K. Dietary flax seed in prevention of hypercholesterolemic atherosclerosis. Atherosclerosis 1997;132(1):69-76. [MEDLINE: 9247361].
59. Rodríguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney International 2001;59(5):1626-40. [MEDLINE: 11318933].
60. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al.Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108(17):2154-69. [MEDLINE: 14581387].
61. Singal PK, Yates JC, Beamish RE, Dhalla NS. Influence of reducing agents on adrenochrome-induced changes in the heart. Archives of Pathology & Laboratory Medicine 1981;105(12):664-9. [MEDLINE: 6895456].
62. Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla NS. Role of free radicals in catecholamine-induced cardiomyopathy. Canadian Journal of Physiology & Pharmacology 1982;60(11):1390-7. [MEDLINE: 7151008].
63. Singal PK, Beamish RE, Dhalla NS. Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Advances in Experimental Medicine & Biology 1983;161:391-401. [MEDLINE: 6869078].
64. Singal PK, Khaper N, Palace V, Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovascular Research 1998;40(3):426-32. [MEDLINE: 10070480].
65. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases 2008;51(3):445-54. [MEDLINE: 18295060].
66. StataCorp. 2005. Stata Statistical Software: Release 9 College Station, TX: StataCorp LP.
67. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purification 2001;19(2):143-51. [MEDLINE: 11150801].
68. Toborek M, Wasik T, Drodz M, Klin M, Magner-Wrobel K, Kopieczna-Grzebieniak E. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism: Clinical & Experimental 1992;41(11):1229-32. [MEDLINE: 1435296].
69. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al.Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine 2005;353(3):238-48. [MEDLINE: 16034009].
70. Wohaieb SA, Godin DV. Alterations in free radical tissue-defense mechanisms in streptozocin-induced diabetes in rat. Effects of insulin treatment. Diabetes 1987;36(9):1014-8. [MEDLINE: 3301471].
71. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine 2000;342(3):154-60. [MEDLINE: 10639540].
72. Zoccali C, Mallamaci F, Tripepi G. AGEs and carbonyl stress: potential pathogenetic factors of long-term uraemic complications. Nephrology Dialysis Transplantation 2000;15 Suppl 2:7-11. [MEDLINE: 11051031].
73. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, et al.Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. Journal of the American Society of Nephrology 2002;13(2):490-6. [MEDLINE: 11805179].
74. Perkovic V, Venkataraman V, Cooper B, Zoungas S, Webster AC. Antioxidants for chronic kidney disease. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008176].